These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 7780637)

  • 1. Inhibition of morphine withdrawal by the association of RB 101, an inhibitor of enkephalin catabolism, and the CCKB antagonist PD-134,308.
    Maldonado R; Valverde O; Ducos B; Blommaert AG; Fournie-Zaluski MC; Roques BP
    Br J Pharmacol; 1995 Mar; 114(5):1031-9. PubMed ID: 7780637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
    Ruiz F; Fournié-Zaluski MC; Roques BP; Maldonado R
    Br J Pharmacol; 1996 Sep; 119(1):174-82. PubMed ID: 8872371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin B antagonists strongly potentiate antinociception mediated by endogenous enkephalins.
    Valverde O; Maldonado R; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1994 Jul; 270(1):77-88. PubMed ID: 8035345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
    Valverde O; Blommaert AG; Fournié-Zaluski MC; Roques BP; Maldonado R
    Eur J Pharmacol; 1995 Nov; 286(1):79-93. PubMed ID: 8566154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
    Noble F; Blommaert A; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1995 Jan; 273(1-2):145-51. PubMed ID: 7737308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhancement of the effects of a complete inhibitor of enkephalin-catabolizing enzymes, RB 101, by a cholecystokinin-B receptor antagonist in diabetic rats.
    Coudoré-Civiale MA; Méen M; Fournié-Zaluski MC; Boucher M; Roques BP; Eschalier A
    Br J Pharmacol; 2001 May; 133(1):179-85. PubMed ID: 11325808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo occupation of mouse brain opioid receptors by endogenous enkephalins: blockade of enkephalin degrading enzymes by RB 101 inhibits [3H]diprenorphine binding.
    Ruiz-Gayo M; Baamonde A; Turcaud S; Fournie-Zaluski MC; Roques BP
    Brain Res; 1992 Feb; 571(2):306-12. PubMed ID: 1319268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
    Valverde O; Noble F; Beslot F; Daugé V; Fournié-Zaluski MC; Roques BP
    Eur J Neurosci; 2001 May; 13(9):1816-24. PubMed ID: 11359533
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
    Smadja C; Ruiz F; Coric P; Fournié-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1997 Aug; 132(3):227-36. PubMed ID: 9292622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
    Maldonado R; Fournié-Zaluski MC; Roques BP
    Naunyn Schmiedebergs Arch Pharmacol; 1992 Apr; 345(4):466-72. PubMed ID: 1620246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The CCKB antagonist PD-134,308 facilitates rewarding effects of endogenous enkephalins but does not induce place preference in rats.
    Valverde O; Fournie-Zaluski MC; Roques BP; Maldonado R
    Psychopharmacology (Berl); 1996 Jan; 123(2):119-26. PubMed ID: 8741934
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CI 988, an antagonist of the cholecystokinin-B receptor, potentiates endogenous opioid-mediated antinociception at spinal level.
    Xu XJ; Elfvin A; Hao JX; Fournié-Zaluski MC; Roques BP; Wiesenfeld-Hallin Z
    Neuropeptides; 1997 Jun; 31(3):287-91. PubMed ID: 9243527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
    Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski MC; Roques BP
    Pain; 1994 Jul; 58(1):77-83. PubMed ID: 7970841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone.
    Le Guen S; Mas Nieto M; Canestrelli C; Chen H; Fournié-Zaluski MC; Cupo A; Maldonado R; Roques BP; Noble F
    Pain; 2003 Jul; 104(1-2):139-48. PubMed ID: 12855323
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Opposite role of CCKA and CCKB receptors in the modulation of endogenous enkephalin antidepressant-like effects.
    Smadja C; Maldonado R; Turcaud S; Fournie-Zaluski MC; Roques BP
    Psychopharmacology (Berl); 1995 Aug; 120(4):400-8. PubMed ID: 8539320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
    Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
    J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
    Baamonde A; Daugé V; Ruiz-Gayo M; Fulga IG; Turcaud S; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1992 Jun; 216(2):157-66. PubMed ID: 1327810
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Naloxone-induced withdrawal syndrome after administration of selective opioid agonists or after activation of the endogenous enkephalinergic system.
    Maldonado R; Waksman G; Feger J; Roques BP
    Prog Clin Biol Res; 1990; 328():531-4. PubMed ID: 2154817
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101.
    Noble F; Coric P; Turcaud S; Fournié-Zaluski MC; Roques BP
    Eur J Pharmacol; 1994 Mar; 253(3):283-7. PubMed ID: 8200422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of the peptidase inhibitor RB 101 and a CCK-B antagonist strongly enhances antinociceptive responses.
    Maldonado R; Derrien M; Noble F; Roques BP
    Neuroreport; 1993 Jul; 4(7):947-50. PubMed ID: 8369487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.